Repligen Co. (NASDAQ:RGEN) Shares Acquired by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. lifted its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 0.7% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 108,741 shares of the biotechnology company’s stock after acquiring an additional 741 shares during the period. Envestnet Asset Management Inc. owned 0.19% of Repligen worth $13,708,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Andra AP fonden purchased a new position in Repligen during the 2nd quarter worth approximately $25,000. YHB Investment Advisors Inc. acquired a new position in shares of Repligen in the 1st quarter valued at $26,000. International Assets Investment Management LLC purchased a new stake in Repligen in the 2nd quarter valued at $33,000. Lazard Asset Management LLC boosted its stake in Repligen by 206.1% during the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 136 shares during the period. Finally, Rothschild Investment LLC acquired a new stake in Repligen during the 2nd quarter worth $57,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Insider Activity

In related news, VP Ralf Kuriyel sold 4,465 shares of Repligen stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $165.67, for a total transaction of $739,716.55. Following the completion of the sale, the vice president now owns 19,261 shares in the company, valued at approximately $3,190,969.87. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, Director Anthony Hunt sold 22,191 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the transaction, the director now owns 139,840 shares of the company’s stock, valued at $20,328,540.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Ralf Kuriyel sold 4,465 shares of Repligen stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $165.67, for a total transaction of $739,716.55. Following the completion of the sale, the vice president now directly owns 19,261 shares of the company’s stock, valued at $3,190,969.87. The disclosure for this sale can be found here. Company insiders own 1.20% of the company’s stock.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $142.85 on Wednesday. The company has a current ratio of 6.65, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26. The stock has a market cap of $7.98 billion, a price-to-earnings ratio of 571.40, a PEG ratio of 4.14 and a beta of 0.94. The company’s 50-day moving average price is $147.82 and its 200 day moving average price is $154.19. Repligen Co. has a 52 week low of $110.45 and a 52 week high of $211.13.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.33. The firm had revenue of $154.07 million during the quarter, compared to the consensus estimate of $154.11 million. Repligen had a positive return on equity of 3.36% and a negative net margin of 0.32%. The company’s quarterly revenue was down 3.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.53 EPS. As a group, research analysts forecast that Repligen Co. will post 1.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

RGEN has been the topic of a number of research reports. JPMorgan Chase & Co. raised their price target on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a report on Wednesday, July 31st. UBS Group dropped their target price on Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a report on Wednesday, July 31st. Royal Bank of Canada reaffirmed an “outperform” rating and set a $190.00 price target on shares of Repligen in a report on Wednesday, July 31st. Benchmark reissued a “hold” rating on shares of Repligen in a research note on Monday, August 5th. Finally, Wells Fargo & Company began coverage on shares of Repligen in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 target price for the company. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $188.38.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.